Pharmacyclics LLC.
Ibrutinib(Pharmacyclics LLC.)은 Non-Hodgkin Lymphoma 표적 ADC로, Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: targeting B cell signalling, JAK-STAT, ROCK2 and CSF1R pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 92.9% (ClinicalTrials.gov NCT03310619). PK: t½ 4 h. 차별점: novel CC classification predicts sensitivity to targeted kinase inhibitors, specifically the BTK inhibitor ibrutinib.
Non-Hodgkin Lymphoma
Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma
Active
Oncolytic herpes simplex virus type 1 (oHSV)-derived virotherapy, a n
retroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Re
novel CC classification predicts sensitivity to targeted kinase inhibitors, specifically the BTK inhibitor ibrutinib
targeting B cell signalling, JAK-STAT, ROCK2 and CSF1R pathway
T cell activation
apoptosis by Annexin V/PI staining
Biomarkers for early diagnosis and personalized treatment remain under investigation
Resistance to Bruton's tyrosine kinase (BTK) inhibition represents a major clinical challenge in mantle cell lymphoma (MCL)
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Pharmacyclics LLC.
Ibrutinib(Pharmacyclics LLC.)은 Non-Hodgkin Lymphoma 표적 ADC로, Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: targeting B cell signalling, JAK-STAT, ROCK2 and CSF1R pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 92.9% (ClinicalTrials.gov NCT03310619). PK: t½ 4 h. 차별점: novel CC classification predicts sensitivity to targeted kinase inhibitors, specifically the BTK inhibitor ibrutinib.
Non-Hodgkin Lymphoma
Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma
Active
Oncolytic herpes simplex virus type 1 (oHSV)-derived virotherapy, a n
retroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Re
novel CC classification predicts sensitivity to targeted kinase inhibitors, specifically the BTK inhibitor ibrutinib
targeting B cell signalling, JAK-STAT, ROCK2 and CSF1R pathway
T cell activation
apoptosis by Annexin V/PI staining
Biomarkers for early diagnosis and personalized treatment remain under investigation
Resistance to Bruton's tyrosine kinase (BTK) inhibition represents a major clinical challenge in mantle cell lymphoma (MCL)
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.